These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 23606708)

  • 21. Boceprevir-based triple therapy to rescue HCV genotype 1/HBV dually infected patients refractory to peginterferon plus ribavirin combination therapy in Taiwan.
    Hsieh MH; Yeh ML; Su TH; Liu TW; Huang CF; Huang CI; Wang SC; Huang JF; Dai CY; Kao JH; Chuang WL; Chen PJ; Liu CJ; Yu ML
    J Formos Med Assoc; 2018 Jun; 117(6):497-504. PubMed ID: 28694000
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Triple therapy with first generation HCV protease inhibitors: lead-in or no lead-in phase?
    Pascale A; Serfaty L
    J Hepatol; 2013 Feb; 58(2):391-4. PubMed ID: 23063419
    [TBL] [Abstract][Full Text] [Related]  

  • 23. STARTVerso1: A randomized trial of faldaprevir plus pegylated interferon/ribavirin for chronic HCV genotype-1 infection.
    Ferenci P; Asselah T; Foster GR; Zeuzem S; Sarrazin C; Moreno C; Ouzan D; Maevskaya M; Calinas F; Morano LE; Crespo J; Dufour JF; Bourlière M; Agarwal K; Forton D; Schuchmann M; Zehnter E; Nishiguchi S; Omata M; Kukolj G; Datsenko Y; Garcia M; Scherer J; Quinson AM; Stern JO;
    J Hepatol; 2015 Jun; 62(6):1246-55. PubMed ID: 25559324
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Refinement of stopping rules during treatment of hepatitis C genotype 1 infection with boceprevir and peginterferon/ribavirin.
    Jacobson IM; Marcellin P; Zeuzem S; Sulkowski MS; Esteban R; Poordad F; Bruno S; Burroughs MH; Pedicone LD; Boparai N; Deng W; DiNubile MJ; Gottesdiener KM; Brass CA; Albrecht JK; Bronowicki JP
    Hepatology; 2012 Aug; 56(2):567-75. PubMed ID: 22619063
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Boceprevir: a protease inhibitor for the treatment of chronic hepatitis C.
    Foote BS; Spooner LM; Belliveau PP
    Ann Pharmacother; 2011 Sep; 45(9):1085-93. PubMed ID: 21828346
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan.
    Kumada H; Toyota J; Okanoue T; Chayama K; Tsubouchi H; Hayashi N
    J Hepatol; 2012 Jan; 56(1):78-84. PubMed ID: 21827730
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and Safety of Direct Acting Antivirals for the Treatment of Mixed Cryoglobulinemia.
    Emery JS; Kuczynski M; La D; Almarzooqi S; Kowgier M; Shah H; Wong D; Janssen HLA; Feld JJ
    Am J Gastroenterol; 2017 Aug; 112(8):1298-1308. PubMed ID: 28291241
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Boceprevir for chronic HCV genotype 1 infection in patients with prior treatment failure to peginterferon/ribavirin, including prior null response.
    Vierling JM; Davis M; Flamm S; Gordon SC; Lawitz E; Yoshida EM; Galati J; Luketic V; McCone J; Jacobson I; Marcellin P; Muir AJ; Poordad F; Pedicone LD; Albrecht J; Brass C; Howe AY; Colvard LY; Helmond FA; Deng W; Treitel M; Wahl J; Bronowicki JP
    J Hepatol; 2014 Apr; 60(4):748-56. PubMed ID: 24362076
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of chronic hepatitis C genotype 1 early responders with 36 week pegylated interferon and ribavirin therapy.
    Sood A; Midha V; Goyal O
    Ann Hepatol; 2014; 13(5):503-9. PubMed ID: 25152982
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Low Efficacy of Pegylated Interferon plus Ribavirin plus Nitazoxanide for HCV Genotype 4 and HIV Coinfection.
    Macías J; López-Cortés LF; Téllez F; Recio E; Ojeda-Burgos G; Ríos MJ; Rivero-Juárez A; Delgado M; Rivas-Jeremías ; Pineda JA
    PLoS One; 2015; 10(12):e0143492. PubMed ID: 26640956
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Boceprevir: a protease inhibitor for the treatment of hepatitis C.
    Chang MH; Gordon LA; Fung HB
    Clin Ther; 2012 Oct; 34(10):2021-38. PubMed ID: 22975763
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial.
    Jacobson IM; Dore GJ; Foster GR; Fried MW; Radu M; Rafalsky VV; Moroz L; Craxi A; Peeters M; Lenz O; Ouwerkerk-Mahadevan S; De La Rosa G; Kalmeijer R; Scott J; Sinha R; Beumont-Mauviel M
    Lancet; 2014 Aug; 384(9941):403-13. PubMed ID: 24907225
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sofosbuvir plus ribavirin for hepatitis C virus-associated cryoglobulinaemia vasculitis: VASCUVALDIC study.
    Saadoun D; Thibault V; Si Ahmed SN; Alric L; Mallet M; Guillaud C; Izzedine H; Plaisier A; Fontaine H; Costopoulos M; Le Garff-Tavernier M; Hezode C; Pol S; Musset L; Poynard T; Cacoub P
    Ann Rheum Dis; 2016 Oct; 75(10):1777-82. PubMed ID: 26567178
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Protease inhibitors for the treatment of chronic hepatitis C genotype-1 infection: the new standard of care.
    Pearlman BL
    Lancet Infect Dis; 2012 Sep; 12(9):717-28. PubMed ID: 22647717
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An inadequate dose of ribavirin is related to virological relapse by chronic hepatitis C patients treated with pegylated interferon alpha-2b and ribavirin.
    Ogawa E; Furusyo N; Kajiwara E; Takahashi K; Nomura H; Tanabe Y; Satoh T; Maruyama T; Nakamuta M; Kotoh K; Azuma K; Dohmen K; Shimoda S; Hayashi J;
    J Infect Chemother; 2012 Oct; 18(5):689-97. PubMed ID: 22450877
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Peginterferon alpha-2a (40 KD) plus ribavirin for the treatment of chronic hepatitis C in Japanese patients.
    Kuboki M; Iino S; Okuno T; Omata M; Kiyosawa K; Kumada H; Hayashi N; Sakai T
    J Gastroenterol Hepatol; 2007 May; 22(5):645-52. PubMed ID: 17444850
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Review of boceprevir and telaprevir for the treatment of chronic hepatitis C.
    Wilby KJ; Partovi N; Ford JA; Greanya E; Yoshida EM
    Can J Gastroenterol; 2012 Apr; 26(4):205-10. PubMed ID: 22506260
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of dialysis patients with chronic hepatitis C using pegylated interferon and low-dose ribavirin.
    Carriero D; Fabrizi F; Uriel AJ; Park J; Martin P; Dieterich DT
    Int J Artif Organs; 2008 Apr; 31(4):295-302. PubMed ID: 18432584
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [HCV reinfection after liver transplantation - management and first experiences with telaprevir-based triple therapy].
    Herzer K; Papadopoulos-Köhn A; Timm J; Paul A; Jochum C; Gerken G
    Dtsch Med Wochenschr; 2013 Sep; 138(36):1759-64. PubMed ID: 24002874
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Retreatment with telaprevir combination therapy in hepatitis C patients with well-characterized prior treatment response.
    Muir AJ; Poordad FF; McHutchison JG; Shiffman ML; Berg T; Ferenci P; Heathcote EJ; Pawlotsky JM; Zeuzem S; Reesink HW; Dusheiko G; Martin EC; George S; Kauffman RS; Adda N
    Hepatology; 2011 Nov; 54(5):1538-46. PubMed ID: 22045671
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.